Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a research note issued to investors on Tuesday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Evogene Stock Performance

EVGN stock opened at $1.78 on Tuesday. Evogene has a fifty-two week low of $1.20 and a fifty-two week high of $10.40. The company has a market cap of $9.54 million, a price-to-earnings ratio of -0.40 and a beta of 1.30. The business’s 50-day moving average is $1.60 and its two-hundred day moving average is $2.87.

Institutional Investors Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Renaissance Investment Group LLC acquired a new stake in shares of Evogene Ltd. (NASDAQ:EVGN) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm acquired 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Institutional investors and hedge funds own 10.40% of the company’s stock.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.